SCHEDULE: Cormorant Asset Management Discloses Rallybio Stake

Cormorant Asset Management, LP and Bihua Chen have reported beneficial ownership of 400,000 shares, representing 7.56% of Rallybio Corp's common stock.

Summary

• Cormorant Asset Management, LP, an investment adviser, and Bihua Chen have jointly filed a Schedule 13G, indicating their beneficial ownership of Rallybio Corp common stock.
• The filing discloses ownership of 400,000 shares of common stock, representing 7.56% of the class.
• The shares are held by Cormorant Funds, which have the right to receive dividends and proceeds from the sale of these shares.
• Cormorant Global Healthcare Master Fund, LP, a specific Cormorant Fund, has the right to receive dividends or proceeds from the sale of more than 5% of the shares.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on an existing ownership stake and does not contain new operational or financial performance data, nor does it indicate any immediate strategic shifts.

Positives

• Significant ownership stake of 7.56% in Rallybio Corp by Cormorant Asset Management and Bihua Chen.
• The filing indicates that the shares are held in the ordinary course of business, suggesting a standard investment approach.

Risks

• The filing does not explicitly detail any risks associated with Rallybio Corp's business operations or financial performance.
• Potential for future changes in ownership or investment strategy by Cormorant Asset Management, which could impact Rallybio's stock.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Rallybio Corp. It solely reports on the ownership stake of Cormorant Asset Management, LP and Bihua Chen.

Management Comments

• "The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein."
• "The Cormorant Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares reported herein."
• "Cormorant Global Healthcare Master Fund, LP, a Cormorant Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the shares."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Cormorant Asset Management, LP and Bihua Chen indicates a significant investment in Rallybio Corp, a biotechnology company. Such filings often signal a substantial interest from institutional investors, which can be a positive indicator for the company's prospects, though the specific strategic intent behind the investment is not detailed here.

Stakeholder Impact

• Shareholders: May view the increased institutional ownership as a sign of confidence in Rallybio Corp, potentially influencing share price. However, the passive nature of the filing suggests no immediate intent to influence control.
• Management of Rallybio Corp: Will be aware of the significant stake held by Cormorant Asset Management, LP, which may influence future strategic discussions or investor relations efforts.
• Potential Investors: This filing provides transparency on a major shareholder, which can be a factor in investment decisions.

Next Steps

• Monitor future filings by Cormorant Asset Management, LP and Bihua Chen for any changes in their ownership stake in Rallybio Corp.
• Observe Rallybio Corp's future financial reports and strategic announcements for insights into the company's performance and direction.

Key Dates

Keywords

Rallybio Corp, Schedule 13G, Cormorant Asset Management, Bihua Chen, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing